** Shares of Regulus Therapeutics RGLS.O more than double to $7.79 premarket
** Novartis offers to buy Regulus for $7/shr cash upfront and another $7/shr on hitting certain regulatory milestones for kidney disease drug farabursen
** Offer worth $800 mln on upfront price
** RGLS shares have already more than doubled this year through last close
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。